MedicaMetrix, Inc., today announced receiving CE mark approval for ProstaMetrix™, a minimally invasive medical device utilizing a fingertip optical encoder, associated controller and battery pack. This approval allows MedicaMetrix to progress its plans for international expansion.
ProstaMetrix enables early evaluation of prostate health through accurate volumetric measurements, differentiating patients at higher risk and mitigating uncertainty. Patients benefit by avoiding invasive, higher-risk procedures, having better care management for both prostate cancer and BPH and thus, a better quality of life.
MedicaMetrix was a recipient of the Accelerator Loan program in 2012. This program was created by the MLSC as a funding program intended for early-stage life sciences companies in Massachusetts.